Australia's largest stock trading and investment forum Australia's #1 stock forum

I disagree. Have a look at coviu as a partner compared to a...

First 22 Last

Share
Profile

Follow
Yenom23

1,261 Posts.

584

10/08/20

20:59

Post #: 46436666
Share

Originally posted by Griffin007 ↑

@Yenom23 Good points but I like their competitor RAP a bit better due to the fact that they tend to have a better and direct global reach and also have a partnership with Coviu.

I also view any kind of sign up with BNPL as a bad sign that translates to me " we didnt have enough customers that could use their credit card, we were wondering if this will work", which achieves nothing but to put higher pressure on margin.They have also done a recent CR, What is their cash like right now?

Expand

I disagree. Have a look at coviu as a partner compared to a $10bn Pharma in CIPLA who have secured the Aussie rights for the RSH product - it sort of legitimises the potential of the product if you have a massive backer. Also RSH have the confidence to put out a $6-8m revenue number and RAP refuses to when I listened to their Last conference call.
Let’s see which goes better - both about 15c
RSH also has a CEO who has created a sleep apnea company from scratch with Resmed as a seed investor
And he got bght out - RAP CEO doesn’t have anywhere near that track record

Last edited by Yenom23: 10/08/20
4 Upvote

2 Great analysis

Reply

There are more pages in this discussion • 69 more messages in this thread...

First 22 Last